Late response to low-dose imatinib in patients with chronic phase chronic myeloid leukemia

Imatinib was the first BCR-ABL tyrosine kinase inhibitor to become clinically available. In this study, we retrospectively evaluated the long-term efficacy of low-dose imatinib (final maintenance dose

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of hematology 2012-09, Vol.96 (3), p.357-363
Hauptverfasser:	Takami, Akiyoshi, Ohtake, Shigeki, Morishita, Eriko, Terasaki, Yasushi, Fukushima, Toshihiro, Kurokawa, Toshiro, Sugimori, Naomi, Matano, Sadaya, Ohata, Kinya, Saito, Chizuru, Yamaguchi, Masaki, Hosokawa, Kohei, Yamazaki, Hirohito, Kondo, Yukio, Nakao, Shinji
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Aged, 80 and over Antineoplastic Agents - administration & dosage Benzamides Biological and medical sciences Child Female Hematologic and hematopoietic diseases Hematology Humans Imatinib Mesylate Leukemia, Myeloid, Chronic-Phase - drug therapy Leukemia, Myeloid, Chronic-Phase - mortality Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Male Medical sciences Medicine Medicine & Public Health Middle Aged Oncology Original Article Piperazines - administration & dosage Protein Kinase Inhibitors - administration & dosage Pyrimidines - administration & dosage Retrospective Studies Treatment Outcome Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Imatinib was the first BCR-ABL tyrosine kinase inhibitor to become clinically available. In this study, we retrospectively evaluated the long-term efficacy of low-dose imatinib (final maintenance dose
ISSN:	0925-5710 1865-3774
DOI:	10.1007/s12185-012-1155-1